Direct-to-Patient Healthcare Firm Ro Nets $150M to Expand B2B Solutions, Patient Experience

Direct-to-patient healthcare company Ro announced in a press release it has raised $150 million from existing investors Tuesday (Feb. 15), along with the launch of Ro Derm, a digital skincare clinic.

“In less than five years, Ro has become the only company to combine nationwide telemedicine, in-home care, diagnostics, labs and pharmacy services,” Zachariah Reitano, co-founder and CEO of Ro, said in the news release.

“With this funding, Ro can accelerate our pursuit of revolutionizing healthcare by building accessible, impactful and trusted care that people want. This year, that means debuting a unified, single-branded care experience for our patients and further enabling other healthcare companies to benefit from the patient-centric technology and services we’ve built,” Reitano said.

Ro Derm is one of three branded offerings from the company, along with Ro Mind, a digital mental health clinic, and Ro Pharmacy, a cash-pay online pharmacy.

The past year has been a busy one for Ro. Last March, the company raised $500 million, pulling in cash from an array of venture funders.

Three months later, the company acquired at-home-testing provider Kit to expand Ro’s platform’s lab and diagnostics capabilities.

Kit makes doctor-ordered, customizable tests for home delivery, letting patients administer the tests — things like finger pricks for blood tests or weight measurement tools — using the on-demand virtual and video support through Kit’s app.

Read more: Ro Acquires Kit To Expand At-Home Medical Testing

This year, Ro says it will roll out one Ro-branded online and mobile platform, where patients can access all of the company’s care and pharmacy services.

“This single destination will support patients’ needs across mental health, women’s health, men’s health, fertility, metabolic health and skincare,” the company said. “The unified platform will combine all of Ro’s vertically integrated capabilities including virtual and in-home care, at-home diagnostics, labs and pharmacy fulfillment.”

Ro says it will also continue expanding its B2B offerings, which are already being used by health systems, labs, clinical trials operators, digital health companies and Fortune 100 companies throughout the country.